-
Identification and management of patients at increased risk for breast cancer
05 Feb 2025 20:00 GMT
… breast cancers (particularly on the same side of the family), early-onset breast cancer (breast cancer … risk for breast cancer due to family history demonstrating that more breast cancers were … daily for 3 years) and anastrozole (1 mg daily for 5 …
-
The Expanding Role of CDK 4/6 Inhibitors in Breast Cancer Treatment
31 Jan 2025 18:18 GMT
… . For endocrine-susceptible breast cancers, the next line … ) with/without anastrozole in patients with HR+… metastatic breast cancer. Presented at: San Antonio Breast Cancer Symposium; … ‒ metastatic breast cancer: phase 1b study. NPJ Breast Cancer. 2022; …
-
Fulvestrant Yields No OS Differences Vs Anastrozole in HR+ Breast Cancer
23 Jan 2025 23:48 GMT
… ) compared with anastrozole (Arimidex) in the … with histologically confirmed breast cancer, positive HR … anastrozole in endocrine therapy–naive women with hormone receptor–positive advanced breast cancer … Arimidex in a subset of patients with breast cancer. …
-
From Abemaciclib to Trastuzumab Deruxtecan: Highlights From the 2024 San Antonio Breast Cancer Symposium
20 Jan 2025 18:12 GMT
… of letrozole (Femara; Novartis), anastrozole (Arimidex; AstraZeneca), exemestane, or fulvestrant … ;www.oncologynewscentral.com/breast-cancer/trastuzumab-deruxtecan-outperforms- … approvals highlight advances in breast cancer care. Pharmacy Times. …
-
Ribociclib Combo May Provide Benefit to Certain Breast Cancer Subtypes
23 Dec 2024 22:00 GMT
… HER2E intrinsic subtypes of breast cancer, according to a subgroup … , HER2-negative advanced breast cancer. Patients were randomized … letrozole (Femara)/anastrozole (Arimidex) and goserelin or physician … +/HER2- advanced breast cancer (ABC): a subgroup …
-
Experts Highlight Advances and Future Directions for Adjuvant Ribociclib in HR+/HER2– Breast Cancer
19 Dec 2024 15:00 GMT
… consisted of Femara (letrozole) or Arimidex (anastrozole) for at least five years … Operating Officer of the Translational Breast Cancer Research Consortium and co-chair … patient advocate living with metastatic breast cancer for 10 years, also participated …
-
Certain Breast Cancer Subtypes May Derive a Greater Benefit With Ribociclib Combo vs Chemo
13 Dec 2024 11:48 GMT
… HER2E intrinsic subtypes of breast cancer treated with ribociclib (Kisqali … , HER2-negative advanced breast cancer. Patients were randomized … letrozole (Femara)/anastrozole (Arimidex) and goserelin or … +/HER2- advanced breast cancer (ABC): a subgroup …
-
Palbociclib Plus Anti-HER2 and Endocrine Therapy Prolongs PFS in HR+/HER2+ Breast Cancer
13 Dec 2024 11:46 GMT
… with breast cancer, and about 15% to 20% of breast cancer overexpress … plus endocrine therapy of letrozole, anastrozole, exemestane, or fulvestrant (n = … HER-positive metastatic breast cancer. Presented at: San Antonio Breast Cancer Conference; December …
-
Looking Ahead After Kisqali’s FDA Approval for Adjuvant Treatment of Early Breast Cancer
11 Dec 2024 00:12 GMT
… consisted of Femara (letrozole) or Arimidex (anastrozole) for at least five years … Operating Officer of the Translational Breast Cancer Research Consortium and co-chair … patient advocate living with metastatic breast cancer for 10 years, also participated …
-
Chemotherapy-Free Regimen Shows Promise in HER2+/HR+ Metastatic Breast Cancer
05 Dec 2024 20:44 GMT
… receptor–positive metastatic breast cancer.
Progression-free survival … –positive metastatic breast cancer. The addition … ), letrozole (Femara), anastrozole (Arimidex), or gonadotropin-releasing hormone … receptor positive metastatic breast cancer – Second interim …
About
© 1995-2025